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Evidence from clinical trials as well as from studies performed in animal models suggest that both amyloid and tau pathologies
function in concert with other factors to cause the severe neurodegeneration and dementia in Alzheimer’s disease (AD) patients.
Accumulating data in the literature suggest that microRNAs (miRNAs) could be such factors. These conserved, small nonprotein-
coding RNAs are essential for neuronal function and survival and have been implicated in the regulation of key genes involved in
genetic and sporadic AD. The study of miRNA changes in AD mouse models provides an appealing approach to address the cause-
consequence relationship between miRNA dysfunction and AD pathology in humans. Mouse models also provide attractive tools
to validate miRNA targets in vivo and provide unique platforms to study the role of speciﬁc miRNA-dependent gene pathways in
disease. Finally, mouse models may be exploited for miRNA diagnostics in the ﬁght against AD.
1.Introduction
Alzheimer’s disease (AD) is the most common form of
dementia worldwide. It is characterized by the accumu-
lation of extracellular amyloid (senile) plaques, composed
mainly of Aβ peptides, and intracellular neuroﬁbrillary
tangles, containing abnormally aggregated and hyperphos-
phorylated Tau protein. The Aβ peptides are generated
by the sequential cleavage of Amyloid precursor protein
(APP) by β-secretase (BACE1-dependent) and γ-secretase
(PSEN/presenilin-dependent).Basedonthediscoveryofrare
familial forms of AD caused mutations in the APP and PSEN
genes, Hardy and Selkoe proposed the “amyloid cascade
hypothesis”, which suggests that Aβ overproduction alone
is suﬃcient to trigger the molecular events leading to both
tangleformationandneuronalcelldeath[1,2].Overthepast
two decades, several breakthroughs have been made with
regard to modeling AD pathology in vivo in mice, providing
important tools for various areas of basic and translational
research. Several AD mouse models harboring human APP,
PSEN, and/or MAPT (Tau) transgenes support to some
extent the amyloid cascade hypothesis; however, recent
clinical trials in humans suggest that amyloid-dependent
signaling pathways are insuﬃcient to cause the severe
neurodegeneration and dementia in AD patients [3–5]. It
is therefore perhaps not surprising that most, if not all, AD
mouse models, albeit displaying massive Aβ deposits and/or
tangles, do not recapitulate the full-blown neuropathological
biochemical, cellular, and morphological changes observed
in AD brain [6–8]. This opens the door to the identiﬁcation
of novel factors important for AD development, which
could equally serve as potential diagnostic and therapeutic
tools.
The past years have witnessed an explosion of papers
linking microRNA (miRNA) dysfunction to human disease,
includingcancer,cardiology,liverdisease,viralinfection,and
many others. Perhaps expectedly, mounting evidence also
involve miRNAs in neurodegenerative disorders, with poten-
tial implications in AD [9, 10], Parkinson’s disease (PD)
[11], Huntington’s disease (HD) [12, 13], frontotemporal
dementia (FTD) [14, 15], and amyotrophic lateral sclerosis
(ALS) [16]. Because of the rapid growth of miRNA research
in general, it is likely other neurodegenerative disorders will
soon be added to this list.2 International Journal of Alzheimer’s Disease
Recent RNA deep sequencing eﬀorts have identiﬁed
more than 1400 miRNA genes in the human genome (700
in mice) (miRBase.org). Several of these are speciﬁcally
expressed in the brain, where they are proposed to function
in neuronal processes such as neurite outgrowth and synapse
formation [17, 18]. The biogenesis and mode of action
of miRNA molecules in mammals is complex and has
extensively been reviewed elsewhere (see, e.g., [19–22]).
In short, miRNA precursors (pre-miRs) are cleaved in
the cytoplasm by the RNase Dicer to produce small (∼
21nt in length) single-stranded nonprotein-coding RNAs.
These latter function as part of the RNA-induced silencing
complex (RISC), which targets speciﬁc mRNA transcripts
with imperfect complementarity. Binding of the miRNA
to its target leads to translation inhibition and/or mRNA
degradation [23, 24], which ultimately leads to down-
regulation of the encoded protein. It is predicted that 25
to 70% of all protein-coding genes can be regulated by
miRNAs, depending on the developmental, cellular, and/or
physiological context. Moreover, each miRNA can target
up to several hundred transcripts in vivo,t h u sp o t e n t i a l l y
regulating multiple biological pathways, including those
implicated in neuronal survival [25]. It is therefore not
surprising that genetic ablation of Dicer in the brain, which
l e a d st oa no v e r a l lr e d u c t i o ni nm i R N Ap r o d u c t i o n ,r e s u l t s
in rapid neurodegeneration [26–28].
The somewhat humble introduction of miRNAs in the
AD ﬁeld came in 2007 when Lukiw studied the expression
levels of 13 brain miRNAs in control and AD patients,
some of which were speciﬁcally altered in disease [29].
Since then, several groups have performed global miRNA
expressionanalysisofADbrain[9,10,29–31]andperipheral
system [32, 33]. These proﬁling experiments tend to show a
trendtowardstheidentiﬁcationof“ADorneurodegenerative
disease-speciﬁc” miRNAs, including miR-29, miR-9, miR-
15a, miR-181c, miR-101, miR-106b, miR-146a, and miR-
107, which have been identiﬁed in two or more indepen-
dent studies. Interestingly, several of these miRNAs may
have a direct role in modulating APP (miR-106, miR-
101) [34–36] or BACE1 (miR-29, miR-107) [9, 37–39]
expression, therefore potentially contributing to increase
amyloid production. Because (1) miRNAs regulate APP
and BACE1 expression, whose increased protein levels are
linked to genetic and sporadic AD, respectively (reviewed
in [21, 40]) and (2) miRNAs control several pathways
involved in neuronal function, inﬂammation and survival,
miRNA research provides an interesting new perspective
to study the underlying mechanisms involved in AD
development.
2. miRNA-Deﬁciency andthe ADBrain
While depleting all miRNAs remain a conceptually crude
approach,itisinterestingtoobserveseveralparallelsbetween
Dicer-deﬁcient brain and AD brain. For instance, neuronal
Dicer conditional knockout (cKO) mice develop progres-
sive neurodegeneration, have reduced brain size, enlarged
ventricles, neuroinﬂammation, apoptosis (in some cases),
as well as impaired dendritic branching, and spine length
[26, 41, 42]. In addition, neuronal Dicer cKO mice exhibit
AD-like hyperphosphorylation of endogenous tau [26],
which is not observed in nontransgenic mice. These latter
results succeed previous studies in the ﬂy linking tau toxicity
to miRNA dysfunction [43]. Interestingly, speciﬁc loss of
Dicer in oligodendrocytes results in axonal degeneration
accompanied by abnormal axonal transport and endogenous
APP accumulation [44]. This model also displays signs of
oxidative stress, and, taken together, these results point
out the importance of Dicer and miRNAs in maintain-
ing neuronal function. Although controversial, one study
suggests that neuronal Dicer deﬁciency promotes learning
and memory, at least at stages prior to neuronal loss [45].
How these observations translate to human disease remains
speculative, but nevertheless provides “proof-of-principle”
that loss (and perhaps gain) of brain miRNA function can
participate in several neuropathological features of AD.
3. miRNA Proﬁles from AD Mice
A p a r tf r o mt h em o r eo b v i o u sr o l eo fm i R N A si nr e g u l a t i n g
the expression of disease-related genes (e.g., APP and
BACE1), it is likely that a combination of more subtle
(direct or indirect) mechanisms alter disease progression
over years, possibly decades. As example, sustained miR-
29 deﬁciency may not only increase BACE1 and Aβ levels,
but also aﬀect DNA methylation and neuronal survival [46,
47]. In addition, it remains diﬃcult to predict whether the
observed changes in miRNA levels in humans are a cause or
consequence of the neurodegenerative process. The study of
miRNA expression proﬁles in AD mouse models may help to
address these questions.
Wang et al. were the ﬁrst to study global miRNA
proﬁles from AD mice using microarrays [48]. For this,
they used the APPSwe-PS1M146L mouse model. Of the
37 diﬀerently expressed miRNAs, several (miR-20a, miR-
29a, miR-125b, miR-128a, and miR-106b) miRNAs were
signiﬁcantly downregulated, while others (miR-34a, let-7,
miR-28, and miR-98) were upregulated. Interestingly, some
miRNAs were similarly shown to be aﬀected in AD brain in
humans,includingmiR-29aandmiR-106b[9,30,31,40,49].
It is noteworthy that miRNA alterations were measured at 3
months of age prior to Aβ plaque formation. In most cases,
miRNA alterations were maintained or even accentuated
during amyloid plaque formation at 6 months of age,
therefore supporting the “cause” hypothesis. The increase
in miR-34a in the mutant mice is proposed to function in
regulating apoptosis via Bcl-2 modulation [48]. In a follow-
up study, the group showed by sensitive miRNA quantitative
RT-PCR that miR-106b is upregulated in 3-month-old AD
mice but downregulated at 6 months [50]. These changes
correlated to some extent with transforming growth factor,
beta receptor II (TβRII) expression, and a putative miR-
106b target gene [50]. While these studies highlight the
importance of microarray validation, they also suggest a
possible transient eﬀect of AD pathology (in this case Aβ
plaque formation) on miRNA expression and vice versa.
More recently, Schonrock et al. studied the eﬀects
of exogenous Aβ on miRNA expression levels in mouseInternational Journal of Alzheimer’s Disease 3
hippocampalneuronsinculture[51].Again,severalmiRNAs
downregulated by Aβ treatment were previously found to be
decreased in human AD brain, including miR-9, miR-181c,
miR-30c, miR-148b, miR-20b, and let-7i. Of interest, certain
miRNAs decreased concomitantly with Aβ pathology pro-
gression in vivo in APP23 mice expressing human APP751
withtheK670N/M671L mutations.Whiletheseobservations
support the “consequence” hypothesis of miRNA dysregu-
lation in AD, it is noteworthy that some miRNA molecules
became aﬀected prior to Aβ plaque formation (like miR-409-
3p and let-7i) similar to what is seen in the Wang et al. study
([48], see above). Furthermore, the expression of certain
miRNAs changed over time (from up- to downregulated or
vice versa), again supporting the transient eﬀect on miRNA
expression during AD development.
While studying the role of actin and the actin-binding
p r o t e i nc o ﬁ l i ni nA D ,Y a oe ta l . observed decreased miR-
103 and miR-107 levels in 4-month old (Aβ plaque bearing)
Tg19959 mice that express mutant APP with KM670/671NL
and V717F FAD mutations [52]. As mentioned above, both
miR-103 and miR-107 were shown to be decreased in MCI
and late-onset AD [10]. The authors further showed that
these miRNA paralogues could eﬀectively regulate coﬁlin
expression in vitro, providing a mechanism for the observed
increase in rod-like structures in this mouse model.
Loss of presenilin function is proposed to underlie mem-
ory impairment and neurodegeneration in the pathogenesis
of AD [53]. Interestingly, small-scale miRNA proﬁling from
Psen1 KO mice with, as a result, reduced γ-secretase activity
and Aβ production, showed that miR-9 down-regulation
coincided with neurodegeneration [54]. It is noteworthy
that miR-9 was shown to be an important regulator of
neurogenesis, both in zebraﬁsh and mice [55, 56]. Based on
these observations, it is tempting to speculate that miR-9,
which is downregulated in AD brain, participates actively in
neuronalmaintenance,andfunctionsinafeedbackloopwith
Aβ.
Candidate miRNA approaches have equally been per-
formed. For instance, Li et al. studied miR-146a expression
in ﬁve diﬀerent AD mouse models, including Tg-2576, Tg-
CRND8, PSAPP, 3xTg-AD, and 5XFAD [57]. This group
had shown earlier that miR-146a expression levels were
increased in AD brain [58]. It turned out that miR-146a
was signiﬁcantly increased in age (4- to 12-month-old) when
compared to young (1- to 2-month-old) mice, and this,
independently of the model tested [57]. Notably, miR-146a
has repeatedly been shown to be implicated in the regulation
of the inﬂammatory response [59]. Moreover, neuroinﬂam-
mation is thought to play a critical role in the pathogenesis
of chronic neurodegenerative diseases including AD [60],
evoking the hypothesis that miR-146a overexpression in
these AD models could reﬂect a defense mechanism against
the deleterious eﬀects of neuroinﬂammation. Interestingly,
synthetic Aβ was shown to induce miR-146a expression
in cultured human neuronal (and glial) cells [58]. Taken
together, the abovementioned observations suggest that
miRNA-regulated gene pathways, such as the miR-146a
pathway, could function both upstream and downstream of
AD pathology (cause and consequence).
4. miRNA-Mediated Regulation of
AD GenesIn Vivo
One of the main challenges in the miRNA ﬁeld is the
identiﬁcation of bona ﬁde target genes. Several genome-wide
methods are currently available to address this question,
including microarray expression analyses following miRNA
transfection/inhibition, Argonaute cross-linked immuno-
precipitation(CLIP)-seqassays,andSILAC-basedproteomic
approaches [61–63]. So far, however, most miRNA studies
involving AD-related genes have relied on artiﬁcial 3 UTR
reporter systems (e.g., luciferase-based assays) as well as
single miRNA gain- or loss-of-function experiments in
cells. While these methods remain indispensable in the
validation of miRNA:mRNA targets, they rarely put both
molecules in their physiological context. In addition, it is
important to consider that some miRNA:mRNA targets
are not conserved in lower organisms such as C. elegans
and Drosophila, making extrapolations to mammalian brain
sometimes diﬃcult (e.g., see [43]).
As of now, most studies addressing the role of miRNAs
in AD gene regulation have focused on APP. These have
lead to the identiﬁcation of at least six miRNAs that could
regulate APP in vitro and in cells, including the miR-20a
family (i.e. miR-20a, miR-17-5p, and miR-106a/b), miR-101,
and miR-16 [40, 64–68]. Interestingly, Liu et al. showed that
miR-16 inhibition in 8-month-old SAMP8 mice, a model for
accelerated senescence, reduced endogenous APP levels by
∼50%[68].Again,theeﬀectsonAβ productionremaintobe
determined. While providing the ﬁrst “proof-of-principle”
of APP regulation by miRNAs in vivo, this study does not
exclude the role of other miRNAs in this process in the
brain. For instance, our preliminary data indicate that APP
mRNA levels are increased in miR-20a/17-5p double KO
mice (Hebert, S.S., unpublished observations). In addition,
itremainsuncertainwhetherothermiR-16homologues,that
is, miR-15a, miR-15b, miR-195, and miR-495 are involved
in APP regulation in vivo. Interestingly, miR-16 family
members have also been implicated in endogenous tau
phosphorylation in neurons [26].
While investigating the molecular mechanisms involved
in endogenous BACE1 overexpression in 6-month-old (Aβ
plaque bearing) 5XFAD [69], O’Connor et al. observed no
signiﬁcant changes in miR-29a, miR-29b, and miR-9 levels,
previously shown to regulate BACE1 in vitro [9], when
compared to nontransgenic controls. Another study suggests
however, that miR-29c (the third miR-29 family member)
overexpression is suﬃcient to decrease endogenous BACE1
p r o t e i nl e v e l si nw i l d - t y p em i c e[ 50]. The functional eﬀects
on BACE1 activity and Aβ production were unfortunately
not evaluated in this latter model. Boissonneault et al.
showed that BACE1 protein increases in 19-month-old
(Aβ plaquebearing)versus4-month-oldAPPSwe-PS1A246E
mice [70], an eﬀect not observed in wild-type mice. Inter-
estingly, two miRNAs shown to regulate murine BACE1
expression in vitro, that is, miR-298 and miR-328 were
downregulatedinthismousemodel.WhetherothermiRNAs
are aﬀected in the 5XFAD and APPSwe-PS1A246E mice
remains to be determined. Lastly, Faghihi et al. showed that4 International Journal of Alzheimer’s Disease
BACE1 protein and BACE1 antisense (noncoding) transcript
levels were increased in 6-week-old Tg19959 mice [71].
Whether decreased miR-103/107 levels observed in this
mouse model (see Yao et al. study above) could contribute
to increase BACE1 remains to be determined. Thus, among
at least ﬁve miRNAs shown to target BACE1 in vitro, that is,
miR-29, miR-9, miR-107, miR-298, and miR-328, no clear
evidencecanbedrawnfromthese mousemodels withregard
to the physiological or pathological regulation of BACE1 by
miRNAs in vivo.
While the abovementioned results are interesting, the
overall contribution of miRNAs in BACE1 and APP expres-
sion regulation remains unclear. The use of gene knockout
mice will be indispensible to make deﬁnitive conclusions
with regard to the role of miRNAs or miRNA gene families
in BACE1, APP, and other AD-related gene expression regu-
lation.Moretransientapproaches,forinstanceusingmiRNA
mimics or inhibitors, will be necessary to address the cause-
consequencerelationshipbetweenmiRNAdysregulationand
ADprogressioninthebrain.Thus,bothclassicalgeneticsand
miRNA functional tools will be necessary to fully investigate
the role of miRNAs in AD mouse models.
5.miRNAs asPotentialDiagnosticTools inAD
Much advancements have been made in the cancer ﬁeld,
for instance, with regard to miRNAs as potential diagnostic
tools, some of which are currently available in the clinic. The
interest in miRNAs in this ﬁeld comes from the fact that they
are readably detected in human body ﬂuids, making them
attractive biological markers. In addition, miRNAs are in
general quite stable when compared to protein and/or other
RNAs,providingreliablemarkersofcellortissuestate.While
a few groups have explored the role of miRNAs in blood and
CSF [32, 33], most AD-based studies have focused mainly
on soluble Aβ (and its derivatives) and tau [72, 73]. In the
future,itwillbeinterestingtocombineand/orcomparethese
specieswithcirculatingmiRNAs,whichcanbefoundinbody
ﬂuids including exosomes [74]. It is noteworthy that groups
havealreadyshownthisapplicabilityinmousemodelsforthe
Duchenne muscular dystrophy and liver injury [75, 76].
6. Conclusions andFuturePerspectives
As summarized above, most studies addressing the role
of miRNAs in AD pathology remain correlative in nature,
and little or no deﬁnitive proof with regard to miRNA
target gene regulation in vivo is currently unavailable.
Addressing these issues is crucial in order to advance our
knowledge of the contribution of miRNAs, if any, in AD
neuropathology. Because mice are genetically homogenous
in nature when compared to humans, they provide unique
tools to study miRNA-regulated gene pathways in AD
development. Human proﬁling studies clearly indicate that
miRNA expression proﬁles are altered in AD brain. Whether
these changes are speciﬁc to AD or reﬂect an overall loss
(or gain) of miRNA function in neurodegenerative disease
remains to be determined using adequate comparative
analyses. The current proﬁling data from AD mice suggest
that miRNA changes equally occur in disease models, yet
some discrepancies still exist. Given our current state of
knowledge, the role of miRNAs in AD development, and
their applicability as diagnostic and perhaps therapeutic
tools into clinic, will require extensive follow-up studies
in both in vitro and animal models. Speciﬁc miRNA gene
knockout and/or transgenic mouse is required to address
these and other fascinating questions.
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